·高德美將發(fā)布多項(xiàng)產(chǎn)品組合的最新數(shù)據(jù),包括RELAX和EXPRESSION研究結(jié)果,展示新型液態(tài) A 型肉毒毒素(RelabotulinumtoxinA)的快速起效特點(diǎn)(最快一天內(nèi)即可顯示效果),以及六個(gè)月以上的高患者滿意度1,2

·塑妍萃® (PLLA-SCA)作為首款經(jīng)過驗(yàn)證的再生型生物刺激劑,其最新體內(nèi)數(shù)據(jù)研究將被公布。研究顯示,與PLLA-GA相比,PLLA-SCA具有更低的炎癥反應(yīng),這對(duì)局部組織反應(yīng)和產(chǎn)品降解具有重要影響,可能延長臨床效果持續(xù)時(shí)間3-12

·全球首個(gè)、規(guī)模最大的藥物驅(qū)動(dòng)體重下降所致面部變化研究結(jié)果,將在會(huì)上發(fā)布,研究顯示,許多患者愿意接受醫(yī)美治療來改善這些變化,其中生物刺激劑和真皮填充劑是最受關(guān)注的治療方案13

·高德美將舉辦專題研討會(huì),探討如何通過醫(yī)美治療改善因藥物導(dǎo)致的面部變化,并舉辦第二場(chǎng)專題研討會(huì),專注于使用瑞藍(lán)® Kysse?(暫未于中國大陸地區(qū)上市)實(shí)現(xiàn)理想唇形的方案

·總體而言,高德美將在大會(huì)上發(fā)布11項(xiàng)電子海報(bào),涵蓋瑞藍(lán)®的最新研究進(jìn)展,并舉辦兩場(chǎng)專題研討會(huì)、四場(chǎng)大師班、五場(chǎng)“專家面對(duì)面”交流會(huì)、一個(gè)沉浸式體驗(yàn)空間及互動(dòng)展位,進(jìn)一步鞏固其在注射類醫(yī)美領(lǐng)域的領(lǐng)導(dǎo)地位

近日,致力于成為全球領(lǐng)先專業(yè)皮膚學(xué)公司的瑞士高德美將于2025年3月27日至29日在摩納哥舉行的第23屆世界美容抗衰老大會(huì)(AMWC)上強(qiáng)勢(shì)亮相?；顒?dòng)內(nèi)容包括:四場(chǎng)大師班、11份研究電子海報(bào)、一個(gè)高德美沉浸式體驗(yàn)空間及展位O2(Ravel展廳)內(nèi)五場(chǎng)“專家面對(duì)面“交流會(huì)。此次全方位的參與將全面展示高德美在注射美學(xué)領(lǐng)域領(lǐng)先的產(chǎn)品組合,滿足當(dāng)下及未來求美者與醫(yī)療專業(yè)人士的多元化需求。

“通過我們?cè)贏MWC 2025的廣泛參與,高德美不僅將與全球醫(yī)美行業(yè)進(jìn)行深入交流,還將展示業(yè)內(nèi)豐富的產(chǎn)品組合。通過數(shù)據(jù)發(fā)布和專家主導(dǎo)的學(xué)術(shù)分享,我們踐行了自己的承諾:將持續(xù)引領(lǐng)注射類醫(yī)美發(fā)展,并為醫(yī)療提供創(chuàng)新解決方案,以更好地滿足求美者當(dāng)前與未來的多樣化需求”，醫(yī)學(xué)博士、高德美全球研發(fā)負(fù)責(zé)人BALDO SCASSELLATI SFORZOLINI表示。

權(quán)威視角聚焦注射美學(xué)熱點(diǎn)話題

近年來,藥物驅(qū)動(dòng)型體重下降呈快速增長趨勢(shì),這種減重往往伴隨程度不一的面部美學(xué)變化。14高德美發(fā)起并完成了目前規(guī)模最大的一項(xiàng)相關(guān)研究,覆蓋五個(gè)國家,超過1300名受訪者,深入探討藥物減重帶來的面部變化。13研究結(jié)果將首次公布,數(shù)據(jù)顯示:93%正在接受減肥治療的人群注意到自己面部出現(xiàn)了不同程度的變化,許多患者表示有意通過醫(yī)美治療改善這些變化,其中生物刺激劑和真皮填充劑成為最常被考慮的治療選擇。13

高德美主辦的“藥物驅(qū)動(dòng)型減重:美學(xué)應(yīng)對(duì)路徑”專題研討會(huì)將于3月27日(星期四)舉行,緊接著在3月28日(星期五)還將舉辦一場(chǎng)大師班,深入探討藥物減重對(duì)面部造成的影響,并詳解醫(yī)美治療如何幫助恢復(fù)面部體積和結(jié)構(gòu)。研討會(huì)將邀請(qǐng)Luiz Avelar博士、Priyanka Chadha博士、Sebastian Cotofana教授、Sabrina Fabi博士、Marcus Morais博士和Andreas Nikolis博士進(jìn)行現(xiàn)場(chǎng)實(shí)操并分享他們的專業(yè)見解。

此外,高德美還將于3月27日(星期四)舉辦“GAIN專家對(duì)話:定義理想唇形”專題研討會(huì),由Sebastian Cotofana教授、Simone Doreian博士、Stephanie Lam博士、Christoph Martschin博士和Andrei Metelitsa博士擔(dān)任講者。該環(huán)節(jié)將通過深度辯論、文化和解剖角度分析、注射實(shí)操演示,深入探討唇部美學(xué)治療的新技術(shù)演變,以及求美者對(duì)自然外觀和真實(shí)觸感的審美標(biāo)準(zhǔn)與偏好。關(guān)于唇部注射技術(shù)的相關(guān)大師班課程也將于3月29日(星期六)進(jìn)一步展開,深入講解治療技術(shù)細(xì)節(jié)。

高德美新數(shù)據(jù)鞏固其產(chǎn)品在滿足患者需求方面的獨(dú)特優(yōu)勢(shì)

高德美將公布III b期EXPRESSION和RELAX臨床研究的新數(shù)據(jù),顯示高德美新型液態(tài)A型肉毒毒素在治療皺眉紋和魚尾紋方面起效迅速、美學(xué)改善顯著。1,2在EXPRESSION研究中,超過50%的受試者在治療后首日即感受到明顯效果;在RELAX研究中,療效可持續(xù)長達(dá)六個(gè)月,驗(yàn)證了READY研究計(jì)劃中觀察到的結(jié)果,超過三分之一患者在六個(gè)月后皺眉紋仍持續(xù)改善。1,2這兩項(xiàng)研究再次證實(shí)患者對(duì)高德美新型液態(tài)A型肉毒毒素的高滿意度,在RELAX研究中,70%的患者表示相比過去的治療,更偏好高德美新型液態(tài)A型肉毒毒素。1,2同時(shí),III期READY研究項(xiàng)目的事后分析補(bǔ)充數(shù)據(jù)也將發(fā)布,顯示無論基線皺紋嚴(yán)重程度如何(中度/重度),接受高德美新型液態(tài)A型肉毒毒素治療的受試者在皺眉紋和魚尾紋的改善,整體幸福感的提升以及療效持續(xù)性方面均有出色表現(xiàn),療效可維持六個(gè)月。15

高德美還將發(fā)布關(guān)于塑妍萃®(PLLA-SCA)的新研究數(shù)據(jù),這是一款經(jīng)過驗(yàn)證的再生型生物刺激劑,新數(shù)據(jù)進(jìn)一步強(qiáng)化其獨(dú)特配方、功效和安全性。3-12一項(xiàng)體內(nèi)對(duì)比研究表明,塑妍萃®在第52周展現(xiàn)出良好的組織響應(yīng)和更慢、可控的降解曲線,同時(shí)與PLLA-GA相比,炎癥反應(yīng)更低。11符合塑妍萃®一貫的高安全性表現(xiàn)。3研究還指出,不同配方的差異可顯著影響局部組織反應(yīng)和產(chǎn)品降解特性,從而影響療效和持續(xù)時(shí)間。11此外,專家共識(shí)確認(rèn)了塑妍萃®在再生醫(yī)美領(lǐng)域的關(guān)鍵地位,并顯示其與阿萊絲汀肌膚護(hù)理®(Alastin®)聯(lián)合使用時(shí)的協(xié)同作用,顯示其覆蓋三層肌膚結(jié)構(gòu)的作用。12,16

關(guān)于瑞藍(lán)®Shaype?(暫未于中國大陸地區(qū)上市)的補(bǔ)充數(shù)據(jù)也將在大會(huì)上發(fā)布。該產(chǎn)品采用高德美專有NASHA HD ?技術(shù),已在加拿大及巴西獲批上市。研究顯示,該產(chǎn)品是目前市面上硬度最高的透明質(zhì)酸注射產(chǎn)品,具有最高的G’值(彈性模量,代表凝膠強(qiáng)度和緊實(shí)度),具備獨(dú)特的仿骨效果17,18。此外,多項(xiàng)合并數(shù)據(jù)及IV期關(guān)鍵研究數(shù)據(jù)將展示,瑞藍(lán)®系列填充劑在改善面部吸引力與年輕感的同時(shí),仍保留或增強(qiáng)98%受試者的自然表情19。這種“自然度+高滿意度”的結(jié)合代表著長期美學(xué)改善19。迄今為止,瑞藍(lán)®是首個(gè)也是唯一一個(gè)有體內(nèi)數(shù)據(jù)來支持其在恢復(fù)及維持自然表情方面有效性的透明質(zhì)酸填充劑品牌。19-22。

包括吉適®和阿萊絲汀肌膚護(hù)理®(Alastin)在內(nèi)的其它研究電子海報(bào),也將共同展現(xiàn)高德美致力于提供既自然又持久的美學(xué)解決方案,幫助實(shí)現(xiàn)求美者多元美學(xué)目標(biāo)。

參考文獻(xiàn)

1. Shridharani S, Coquis-knezek S and Prygova I. Aesthetic improvement and rapid results in glabellar and lateral canthal lines after treatment with the innovative liquid relabotulinumtoxinA formulation. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

2. Ablon G, et al. Subject preference and satisfaction with liquid relabotulinumtoxinA treatment of glabellar lines over 12 months, in a randomized controlled trial. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

3. Galderma. Sculptra EU Instructions For Use 2023

4. Widgegrowl J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds). IMCAS Poster 2024. Paris, France

5. Galderma. Data on file. MA-50526. 43USSA1812 clinical study report. Fort Worth, TX: Galderma Laboratories, L.P. 2022

6. Bohnert K, et al. Randomized, Controlled, Multicentered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid for Improving Skin Quality.

Dermatol Surg 2019;45:718–724

7. Hexsel D, et al. Introducing the L-Lift—A Novel Approach to Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg:

Letters & Communications. 2019

8. Galderma. Data on File (MA-60875)

9. Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi:

10.1093/rb/rbab042

10. Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi:

10.36849/JDD.7791

11. Avelar L, et al. Comparing two biostimulators on the local tissue response and degradation up to 52 weeks in vivo with an indirect comparison to clinical outcomes. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

12. Fabi S, et al. Regenerative aesthetic effects of poly L-lactic acid (PLLA-SCA) treatment. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

13. Nikolis A, Prygova I and Brasatar D. The potential role of biostimulators/dermal fillers to address the impact of medication driven weight loss management treatments on facial appearance. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

14. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg.

2023;39:719-721

15. Ablon G, et al. RelaBoNT-A treatment of glabellar lines and lateral canthal lines of different baseline severity: subgroup analyses of pooled Phase III study data. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

16. Markowitz O, et al. Evaluation of synergistic effects for midface improvement when pairing Sculptra® (PLLA-SCA) with Alastin skincare®: A comparative study. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco

17. Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco

18. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255-61. doi: 10.36849/JDD.8145

19. Nkolis A, et al. Hyaluronic acid fillers preserve natural movement and dynamic expression: data from three postmarketing clinical studies. Presented at AMWC 2025; Mar 27-29, 2025; Monaco

20. Percec, I et al. An Objective, Quantitative, Dynamic Assessment of Hyaluronic Acid Fillers That Adapt to Facial Movement. Plast Reconstr Surg.

2020;145:295e-305e. doi: 10.1097/PRS.0000000000006461

21. Philipp-Dormston WG, et al. Evaluating Perceived Naturalness of Facial Expression After Fillers to the Nasolabial Folds and Lower Face With Standardized Video and Photography. Dermatol Surg. 2018;44(6):826-32. doi: 10.1097/DSS.0000000000001419

22. Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-46. doi:

10.1111/jocd.12961

23. Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting

24. Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at:

TOXINS 2022; July 27-30, 2022; New Orleans, LA

25. Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. ASJ. 2024; sjae131

26. Ablon G, et al. Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study. Dermatol Surg. 2024. doi: 10.1097/DSS.0000000000004470

27. Relfydess® . EU Summary of Product Characteristics

28. Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin

29. Di Gregorio C. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC, March 27-29, 2024, Monaco

30. Nikolis A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1-12.

31. Galderma. Data on file. Subject satisfaction (GAIS) - NASHA and OBT Fillers. 2021

32. Restylane U.S. Instructions For Use. Available online. Accessed January 2025.

33. Kablik J, et al. Comparative Physical Properties of Hyaluronic Acid Dermal Fillers: Dermatologic Surgery 35, 302-312 (2009).

34. Narins RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644-650

35. Talarico S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361-1369

36. Ohrlund A, et al.. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance.

JDD. 2024; 23(1), pp.1332-1336

37. Philipp -Dormston WG, et al. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-6.

38. U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed January 2025 .

39. Galderma. Data on File (MA-46589)

40. Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi:10.1186/1471233414474

41. Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transpl. 2018;27(5):729-738. doi:

10.1177/0963689717725755

42. Asius J, et al. Inventors. US patent US 7,731,758 B2.2010. Available online. Accessed January 2025

43. Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at IMCAS World Congress, January 26-28, 2023, Paris, France

44. Galderma. Data on File (MA-53568)

45. Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/j.1365- 2133.1975.tb05113.x

46. Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915- 22

47. Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48: 101-108. doi:

10.1097/DSS.0000000000003239

48. Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States

49. Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte

Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States

50. Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284-

1288. doi: 10.1111/ijd.16229

51. Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol.

2014;13(4 Suppl):s44-s51

52. Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC, March 30 - April 1, 2023, Monaco

相關(guān)知識(shí)

IMCAS 2025：高德美發(fā)布塑妍萃? 等美學(xué)產(chǎn)品最新數(shù)據(jù)，再次彰顯行業(yè)領(lǐng)導(dǎo)地位
細(xì)胞、干細(xì)胞技術(shù)抗衰成行業(yè)風(fēng)口？業(yè)內(nèi)呼吁醫(yī)美回歸醫(yī)療本質(zhì)
潮流文化視角下的美學(xué)機(jī)遇和挑戰(zhàn) 高德美發(fā)布《前顏NEXT》全球美學(xué)趨勢(shì)報(bào)告
塑妍萃?Sculptra?在華獲批中面部適應(yīng)癥 高德美有力推進(jìn)注射美學(xué)在華全面布局
AAD 2025：高德美展示皮膚學(xué)產(chǎn)品組合最新進(jìn)展，彰顯行業(yè)領(lǐng)導(dǎo)力與增長動(dòng)能
西班牙知名健康醫(yī)療設(shè)備品牌INDIBA英特波將入駐2021成都世界美容抗衰老大會(huì)（AMWC）現(xiàn)場(chǎng)
致敬發(fā)生在中國土地上的醫(yī)療創(chuàng)新，2024“醫(yī)療健康產(chǎn)業(yè)創(chuàng)新力產(chǎn)品榜”發(fā)布
娃哈哈集團(tuán)產(chǎn)品全覽：從經(jīng)典到創(chuàng)新，滿足多元需求
健合集團(tuán)Swisse斯維詩主辦抗衰創(chuàng)新論壇，推動(dòng)醫(yī)美行業(yè)進(jìn)入“口服抗衰新時(shí)代”
健康消費(fèi)需求強(qiáng)勁 美年健康發(fā)力創(chuàng)新產(chǎn)品

網(wǎng)址: AMWC 2025：高德美發(fā)布全產(chǎn)品線創(chuàng)新成果，引領(lǐng)醫(yī)美前沿，滿足行業(yè)需求 http://m.u1s5d6.cn/newsview1085598.html